Vonoprazan vs. Proton Pump Inhibitors for Treatment and Prevention of Gastric and/or Duodenal Ulcers: A Systematic Review with Meta-Analysis

Daniel Martin Simadibrata, Elvira Lesmana, Muhammad Iqbal Adi Pratama, Adrianus Jonathan Sugiharta, Ayers Gilberth Ivano Kalaij, Arzita Diandra Diva Fadhilla, Pojsakorn Danpanichkul, Ari Fahrial Syam, Marcellus Simadibrata

Research output: Contribution to journalArticlepeer-review

Abstract

Introduction: Although Vonoprazan, a potassium-competitive acid blocker, is superior to proton pump inhibitors (PPIs) in treating Helicobacter pylori and erosive esophagitis, its efficacy for treating gastric and/or duodenal ulcers remains controversial. This meta-analysis summarizes the efficacy and safety of Vonoprazan vs. PPI for treating and preventing gastric and/or duodenal ulcers. Methods: Only randomized controlled trials randomizing gastric and/or duodenal ulcer patients, regardless of etiology, into Vonoprazan or any PPI and indexed in Embase, Medline, and CENTRAL until March 2, 2024 were searched. Primary outcomes were ulcer healing rates at Weeks 2, 4, 6, and 8 and recurrence rates at Week 24. Other outcomes included shrinkage rates, any adverse events (AEs), serious AEs (SAEs), and risks of delayed bleeding and perforation. The overall risk ratio (RR) and mean difference were pooled using the random-effects model. The risk of bias was assessed using the Cochrane Risk of Bias 2 (RoB2) Tool. Results: Fifteen studies comprising 43 reports were included in the analysis. Healing rates of gastric and/or duodenal ulcers were similar in both Vonoprazan and PPI groups at all weeks (Week 2 RR 1.02 [95% CI 0.89–1.16]; Week 4 0.99 [95% CI 0.95–1.04]; Week 6 1.00 [95% CI 0.96–1.03]; Week 8 0.99 [95% CI 0.95–1.03]). The recurrence prevention of peptic ulcers was not different in Vonoprazan 10 mg (RR 0.48; 95% CI 0.18–1.27) or 20 mg (0.60; 95% CI 0.28–1.30) to PPI. Shrinkage rates, any AEs, SAEs, and risks of delayed bleeding and perforation were similar in both groups. Conclusion: Vonoprazan is not significantly better than PPI in treating and preventing gastric and/or duodenal ulcers.

Original languageEnglish
Pages (from-to)3863-3874
Number of pages12
JournalDigestive Diseases and Sciences
Volume69
Issue number10
DOIs
Publication statusPublished - Oct 2024

Keywords

  • Meta-analysis
  • Peptic ulcer
  • Post-ESD ulcers
  • Proton pump inhibitor
  • Vonoprazan

Fingerprint

Dive into the research topics of 'Vonoprazan vs. Proton Pump Inhibitors for Treatment and Prevention of Gastric and/or Duodenal Ulcers: A Systematic Review with Meta-Analysis'. Together they form a unique fingerprint.

Cite this